Browse Articles

Discover research articles across all indexed journals

Adaptive multi-level graph representation with optimization-aware attention for robust cell association in 5G V2X networks

Scientific Reports E. S. Phalguna Krishna, Kamaraj Kanagaraj, N. V. RajaSekhar Reddy et al. Jul 01, 2026 DOI: 10.1038/s41598-026-59699-x

Abstract Efficient cell association remains a fundamental challenge in fifth-generation (5G) vehicle-to-everything (V2X) systems due to rapid topology changes, heterogeneous deployments, and stringent latency requirements. Conventional learning-based approaches often rely on shallow representations or independent optimization strategies, limiting their adaptability in dense and highly dynamic environments. To address these issues, this study introduces a multi-level graph representation framework that models interactions between vehicles and base stations across hierarchical spatial structures. The proposed approach integrates contextual node embedding with attention-driven graph learning to capture mobility patterns, signal characteristics, and network load dependencies. Additionally, a training-stage optimization mechanism is incorporated to refine attention parameters, improving convergence behavior without increasing inference complexity. The framework is evaluated using a real-world vehicular mobility dataset, demonstrating consistent improvements in association stability, handover reliability, and overall network performance compared with existing deep learning and graph-based methods. Experimental results show gains in accuracy (94.17%) and F1-score (93.93%), indicating enhanced decision robustness under dynamic conditions. Although validation is conducted on an urban dataset, the proposed architecture provides a scalable foundation for adaptive cell selection in next-generation intelligent transportation systems.

Therapeutic and prophylactic strategies for Ebola caused by Bundibugyo virus

Nature Reviews Drug Discovery Jean B. Nachega, Jean-Jacques Muyembe-Tamfum, Alimuddin Zumla Jul 01, 2026 DOI: 10.1038/d41573-026-00094-6

A 2026 update on myelodysplastic neoplasms: current state, challenges and future directions

Nature Reviews Clinical Oncology Jan Philipp Bewersdorf, Alain Mina, Maximilian Stahl et al. Jul 01, 2026 DOI: 10.1038/s41571-026-01141-2

RS-232 and other forms of grief

Nature C. A. Russell Jul 01, 2026 DOI: 10.1038/d41586-026-01936-4

Tuning Intermediate Adsorption and Interfacial Water Networks via Lattice Strain of NiFe Alloys Boosts Low‐Concentration Nitrate Electroreduction

Advanced Materials Heng Yue, Wan Xie, Da Wan et al. Jul 01, 2026 DOI: 10.1002/adma.73761

ABSTRACT The electrochemical nitrate‐to‐ammonia reduction (NO 3 − RR) in low‐concentration neutral media is often hindered by sluggish mass transfer and competitive hydrogen evolution reaction (HER). Herein, we propose a strategy to introduce lattice strain into a Ni catalyst through the co‐evaporation of a small proportion of Fe heteroatoms. According to in situ spectroscopy and theoretical calculations, the strain effect can optimize the d ‐band center of the Ni active sites, thereby modulating the adsorption strength of key intermediates ( * NO 3 − , * NO 2 , * NO) and enhancing the intrinsic activity for NO 3 − RR. Furthermore, the strained surface can reorganize the interfacial hydrogen‐bond network and modulate the proportion of free water, thereby balancing the supply of active hydrogen ( * H) with the suppression of HER. Consequently, NiFe‐T1.4 achieves remarkable NH 3 Faradaic efficiencies (FE) up to 95.5% and yield rates up to 8.57 mg h −1 cm −2 in neutral low‐concentration (5–50 m m ) nitrate solutions. Furthermore, NiFe‐T1.4 can also be employed as a cathode in a Zn‐NO 3 − battery, delivering a high open‐circuit voltage of 1.53 V and a peak power density of 8.10 mW cm −2 . This work presents a feasible approach to engineering high‐performance catalysts for nitrate‐to‐ammonia conversion by combining lattice strain and interfacial water management.

Designing Strong, Tough, Fire‐Retardant and Self‐Healing Elastomers with Phosphorus/Nitrogen‐ and Biphenyl‐Containing Segments

Advanced Materials Yijiao Xue, Shu Gong, Zhezhe Zhou et al. Jul 01, 2026 DOI: 10.1002/adma.73534

ABSTRACT High‐performance polyurethane (PU) elastomers have demonstrated many important industrial applications in areas such as soft robotics, flexible sensors and electronic devices. However, it has been challenging to design strong and tough elastomers that are capable of fire‐extinguishing and self‐healing due to different governing mechanisms associated with these properties. Here we present a molecular engineering strategy to achieve strong, tough, fire‐retardant, and healable PU elastomers by rationally designing a phosphorus/nitrogen (P/N)‐ and π–π interacting biphenyl‐containing diol as hard segments with side groups. The formation of relatively strong interchain π–π stacking enables the elastomer to achieve superior mechanical and self‐healing properties, while the combination of π–π stacking and P/N elements promotes exceptional fire retardancy. The resultant elastomer displays a record‐high large break strain of ∼2500%, a large toughness (ca. 379 MJ/m 3 ) and a tensile strength of 46 MPa, and a healing efficiency as high as 95% (tensile strength) and 99% (break strain). Also, the elastomer can self‐extinguish with a high limiting oxygen index of 38.6%. We then demonstrate its application for high‐sensitivity multi‐mode tattoo sensors. This work opens new avenues for developing strong, flexible, tough elastomers with multiple integrated functionalities.

Structure of a stand-alone homodimeric nonribosomal peptide synthetase condensation domain reveals occlusion of the canonical carrier-protein interface

Journal of Biological Chemistry Jitendra Singh, Thomas D. Grant, Andrew M. Gulick Jul 01, 2026 DOI: 10.1016/j.jbc.2026.113208

Targeted delivery of topotecan via folic acid functionalized phycocyanin nanoparticles for ovarian cancer.

Journal of Clinical Oncology Satyam Kumar Agrawal, Madhunika Agrawal, Kanwaljit Chopra Jul 01, 2026 DOI: 10.1200/jco.2026.44.19_suppl.86

86 Background: Ovarian cancer remains the deadliest gynecologic malignancy due to late-stage diagnosis and frequent treatment resistance. The aim of the present work was to evaluate improved therapeutic efficacy of topotecan with regards to combating drug resistance in ovarian cancer cells. Methods: Folic acid tagged topotecan loaded phycocyanin nanoparticles were prepared by modified desolvation process. Nanoformulation was characterized in terms of size and shape by electron microscopy. Surface modification was observed by FTIR. The release kinetics of nanoformulation in PBS solutions at pH 7.4 and pH 5.5 was studied to mimic the plasma and lysosomal environment in vitro. The anti-cancer activity was investigated in vitro by MTT assay in resistant (PA-1R) as well as sensitive (PA-1) ovarian cancer cell line. pK and acute toxicity studies were also performed in female mice and safety profiling of nanoformulation was performed by histopathological study in vital organs. Apoptosis involvement was studied using ELISA for measuring anti and pro apoptotic proteins. Expression levels of proteins like ABCG2, ABCB1, PTPRK were studied through RT-PCR assay. Results: Nanoformulation revealed spherical nanoparticles with 72-80 nm size range. The release rate of topotecan from nanoformulation was significantly faster at pH 5.5 throughout 96-h release period than at pH 7.4. Cytotoxic effect of nanoformulation was more pronounced against PA-1R cells as compared to topotecan alone. This was substantiated by various other studies like migration assay and 3D spheroid formation restriction activity. There was 2 fold increase in BAX and almost 7 fold increase in caspase 3 activity after 12 h of incubation. Likewise 4.5 fold decrease in Bcl-2 levels were observed. Altered levels of ABCB1 and PTPRK were modulated by nanoformulation. ABCB1 showed 6 fold increase in nanoformulation treated PA-1R cells as compared to 4 fold increase in case of parent topotecan. Similarly, 2 fold change in PTPRK was observed in nanoformulation treated resistant cells. Although ABCG2 levels showed similar pattern, however difference was not very significant. No toxicity was observed in terms of body weight, feeding habits during 14 days observation period while performing acute toxicity assay, which was confirmed by histopathological analysis. Conclusions: This preliminary characterization of the formulation shows a new insight for improving the therapeutic efficacy of topotecan, by adopting new delivery strategies, using phycocyanin nanoparticles.

Real-world comparative effectiveness and safety of sotorasib versus adagrasib in previously treated KRAS G12C-mutant non-small cell lung cancer: A propensity score-matched cohort study.

Journal of Clinical Oncology Shankar Biswas, Yashasvi Srivastava, Rahul Falodia et al. Jul 01, 2026 DOI: 10.1200/jco.2026.44.19_suppl.282

282 Background: Sotorasib and adagrasib are selective KRAS G12C inhibitors approved for previously treated advanced NSCLC. No head-to-head trial exists, and indirect comparisons from pivotal trials (CodeBreaK 200, KRYSTAL-12) are limited by cross-trial heterogeneity. Real-world comparative effectiveness and safety data are needed to inform treatment selection, particularly given distinct toxicity profiles (e.g., QTc prolongation with adagrasib, hepatotoxicity with sotorasib). Methods: Using the TriNetX Global Collaborative Network (171 healthcare organizations), we identified adults with NSCLC (ICD-10: C34.x) who received sotorasib (Cohort A) or adagrasib (Cohort B) as index therapy. The primary outcome was overall survival (OS). Secondary outcomes included hepatotoxicity, diarrhea, nausea/vomiting, QTc prolongation/arrhythmia, fatigue, intracranial progression, and ILD/pneumonitis. Propensity score matching (1:1) adjusted for age, sex, race/ethnicity, brain/bone/liver/visceral metastases, Charlson comorbidity components, and baseline labs (creatinine, albumin, hemoglobin, LDH, ALP). Kaplan-Meier analysis with log-rank testing and Cox proportional hazards regression were performed. Results: After matching, 461 patients per cohort were analyzed. Median follow-up was 289 days (sotorasib) and 162 days (adagrasib). Median OS was comparable: 392 vs 406 days (HR 0.983; 95% CI, 0.812–1.190; P = 0.859). Safety outcomes are shown in Table 1. Adagrasib was associated with significantly higher risk of QTc prolongation/arrhythmia (HR 0.537; 95% CI, 0.346–0.833; P = 0.005), while hepatotoxicity, GI toxicity, ILD, and intracranial progression rates were similar. Conclusions: In this large real-world propensity score-matched analysis, sotorasib and adagrasib demonstrated comparable OS in previously treated KRAS G12C-mutant NSCLC. Adagrasib was associated with significantly higher QTc prolongation/arrhythmia risk, consistent with known pharmacologic differences. These findings support both agents as viable options with treatment selection guided by patient-specific cardiac risk profiles and comorbidities. Outcomes after propensity score matching (n=461 per cohort). Outcome Sotorasib Adagrasib HR (95% CI) P Median OS, days 392 406 0.983 (0.812–1.190) 0.859 Hepatotoxicity 6.6% 4.3% 1.315 (0.726–2.381) 0.365 Diarrhea 15.6% 14.0% 0.891 (0.606–1.311) 0.559 Nausea/vomiting 16.2% 16.4% 0.662 (0.429–1.020) 0.060 QTc/arrhythmia 9.8% 13.5% 0.537 (0.346–0.833) 0.005 Fatigue 8.6% 9.6% 0.631 (0.374–1.062) 0.080 Intracranial progression 10.1% 6.9% 0.999 (0.578–1.727) 0.997 ILD/pneumonitis 4.0% 3.2% 0.882 (0.420–1.852) 0.741

Chemical Probes to Reveal the Assembly and Dynamics of Wall Teichoic Acids

Journal of the American Chemical Society Gerard J. Porter, Theodore C. Warner, Carolina Ortiz-Cordero et al. Jul 01, 2026 DOI: 10.1021/jacs.6c01990

Feasibility of Meta Quest 2 for tracking upper-limb movements under varying field of view conditions: a pilot study

Scientific Reports Vanina Costa, Rodrigo Garcia-Carmona, Cristina Sánchez et al. Jul 01, 2026 DOI: 10.1038/s41598-026-59977-8

Understanding Ras inhibitor resistance

Nature Reviews Drug Discovery Sarah Crunkhorn Jul 01, 2026 DOI: 10.1038/d41573-026-00091-9

Multidisciplinary management of meningiomas in the era of precision oncology

Nature Reviews Clinical Oncology Majid Assadi, Malik E. Juweid, Philipp Lohmann et al. Jul 01, 2026 DOI: 10.1038/s41571-026-01148-9

Replication-stress-induced chromatin loops protect fork stability

Nature Vincent Gaggioli, Kaustav Sengupta, Ashutosh Choudhury et al. Jul 01, 2026 DOI: 10.1038/s41586-026-10695-1

Organic Photovoltaic Cells for Reliable Energy Generation in Deep Space Environments

Advanced Materials Shuohan Cheng, Yong Cui, Yang Xiao et al. Jul 01, 2026 DOI: 10.1002/adma.73628

ABSTRACT Lightweight, flexible, and capable of high specific power, organic photovoltaic (OPV) cells represent a promising solution for energy generation in deep space. However, their practical operation under such extreme conditions remains in its infancy. Here we reveal that low temperatures reshape the intrinsic energetics and charge dynamics of OPV cells. As temperature decreases, the density of states narrows and the quasi‐Fermi level splitting increases, enhancing the open‐circuit voltage. Yet, the reduced driving force constrains exciton dissociation and charge transport, highlighting the need for next‐generation active layers with enhanced driving forces. Meanwhile, cathode interlayer materials that facilitate charge extraction through interfacial dipole effects demonstrate superior performance at cryogenic temperatures. Flexible OPV cells based on polyimide substrates exhibit remarkable mechanical resilience under such conditions. These findings provide guiding principles for the design of efficient, durable, and adaptable photovoltaic systems for future deep space exploration.

Structural characterization of intermediates in Sec1/Munc18 protein-catalyzed SNARE assembly

Journal of Biological Chemistry Abigail E. Stanton, Isabella Midura, Nanako Shirai et al. Jul 01, 2026 DOI: 10.1016/j.jbc.2026.113352

Questioning the benefit of adjuvant chemotherapy in premenopausal HR+/HER2– early breast cancer: Real-world evidence from an Asian cohort.

Journal of Clinical Oncology Jen-Yu Chuang, Yuan-Ching Chang Jul 01, 2026 DOI: 10.1200/jco.2026.44.19_suppl.39

39 Background: The benefit of adjuvant chemotherapy in premenopausal women with hormone receptor (HR)–positive, HER2-negative early breast cancer remains controversial. Randomized trials such as TAILORx and RxPONDER suggest improved outcomes in younger patients, yet it remains unclear whether this benefit reflects direct cytotoxic effects or chemotherapy-induced ovarian function suppression. Real-world data addressing this question in Asian populations are limited. Methods: We conducted a retrospective cohort study of 3,152 women diagnosed with HR-positive, HER2-negative early breast cancer between 2004 and 2019 at a tertiary medical center. Patients receiving endocrine therapy alone were compared with those receiving chemoendocrine therapy. Primary endpoints included invasive disease-free survival (IDFS), distant metastasis-free survival (DMFS), and overall survival (OS). Multivariable Cox proportional hazards models and restricted cubic splines were used to evaluate age-dependent treatment effects. Results: Among the study cohort, 1,473 patients (47%) received endocrine therapy alone, whereas 1,679 (53%) received chemotherapy in combination with endocrine therapy (chemoendocrine therapy). Overall, adjusted hazard ratios (HRs) associated with chemotherapy tended to be higher in younger patients than in older patients. A total of 1,325 patients (42%) were premenopausal (<50 years). In this subgroup, chemoendocrine therapy was not associated with improved invasive disease-free survival (IDFS; adjusted HR 1.40, 95% CI 0.88–2.24) or overall survival (OS; HR 1.48, 95% CI 0.81–2.69) compared with endocrine therapy alone and was associated with significantly worse distant metastasis-free survival (DMFS; HR 3.46, 95% CI 1.55–7.73). Five-year IDFS, DMFS, and OS were numerically higher among patients treated with endocrine therapy alone. Subgroup analyses demonstrated no survival benefit from chemotherapy across tumor stage, histologic grade, or nodal status, including patients with multiple positive lymph nodes. Conclusions: In this large real-world cohort of premenopausal women with HR-positive, HER2-negative early breast cancer, the addition of chemotherapy to endocrine therapy did not improve survival outcomes. These findings suggest that the observed benefit of chemotherapy in younger patients may largely reflect ovarian function suppression rather than intrinsic chemosensitivity and support a biology-driven, treatment de-escalation approach.

EBV DNA dynamics guide post-local-therapy ICI consolidation in stage II-III pulmonary lymphoepithelioma-like carcinoma.

Journal of Clinical Oncology Minjie Chen Jul 01, 2026 DOI: 10.1200/jco.2026.44.19_suppl.274

274 Background: Immune checkpoint inhibitors (ICIs) improve outcomes in pulmonary lymphoepithelioma-like carcinoma (PLELC). Plasma Epstein–Barr virus (EBV) DNA reflects tumor burden, but how on-treatment EBV DNA dynamics can guide post–local-therapy ICI consolidation remains unclear. Methods: We retrospectively enrolled stage II–III PLELC from four centers treated with definitive surgery and/or radiotherapy, with or without immunotherapy, and ≥1 plasma EBV DNA assessment after definitive local therapy. EBV DNA was measured at baseline (t0), after induction therapy (t1), and after definitive local therapy (t2). Within induction-ICI and non–induction-ICI strata, we evaluated consolidation ICI benefit by (i) EBV DNA status at each timepoint, (ii) molecular trajectories (early clearance, delayed clearance, persistent positivity), and (iii) integrated molecular–radiologic response categories. Cox proportional hazards–based prognostic models were built and compared using Harrell’s C-index. Results: Among 208 patients (84.6% stage III), induction ICI and consolidation ICI were given in 36.5% and 36.1%, respectively. In patients without induction ICI, consolidation ICI improved PFS only in the persistent-positivity trajectory (median PFS: not reached vs 19 months; p = 0.037), with no clear benefit in early or delayed clearance. In patients with induction ICI, benefit was confined to the early-clearance group (72 vs 42 months; p = 0.034). Using integrated molecular–radiologic stratification, non–induction-ICI patients benefited mainly among t1 double non-responders (not reached vs 18 months; p = 0.001) and t2 non-responders (not reached vs 46 months; p = 0.024), whereas induction-ICI patients benefited among t1 and t2 double responders (t1: not reached vs 42 months, p = 0.044; t2: not reached vs 47 months, p = 0.036). A PFS model combining clinical factors with t2 EBV DNA and t2 radiologic response showed good discrimination (C-index 0.763, 95% CI 0.734–0.825) and outperformed t2 EBV DNA alone. Conclusions: Peri-treatment plasma EBV DNA trajectories and integrated EBV DNA–radiologic response refine identification of patients most likely to benefit from consolidation immunotherapy after definitive local therapy in stage II–III PLELC, enabling an interpretable biomarker framework and individualized risk assessment to guide consolidation ICI.

Construction of Isolated Pd <sub>3</sub> Geometry on GaO <sub> <i>x</i> </sub> -Modified Pd/Al <sub>2</sub> O <sub>3</sub> as a Highly Active and Selective Catalyst for Semihydrogenation of Acetylene

Journal of the American Chemical Society Rizheng Jing, Chen Liang, Wenjie Xie et al. Jul 01, 2026 DOI: 10.1021/jacs.6c05181

The application of contrast-enhanced T2-FLAIR MRI in gross tumor target volume determination for radiotherapy of large-volume brain metastases

Scientific Reports Shanshan Du, Yong Yin, Rui Liu et al. Jul 01, 2026 DOI: 10.1038/s41598-026-59974-x